Pharvaris

The company is headquartered in the Netherlands and is listed on Nasdaq.

Deucrictibant is an oral bradykinin B2 receptor antagonist designed to block the pathway that drives swelling attacks in HAE. Pharvaris positions the program around convenience and speed of effect in acute treatment, while also pursuing extended-release dosing for prevention, based on company disclosures in investor updates.

The lead on-demand program reported a pivotal inflection point in December 2025. On December 3, 2025, Pharvaris announced positive topline results from RAPIDe-3, its Phase III study evaluating deucrictibant for on-demand treatment of HAE attacks. The company said the study met its primary endpoint, with a median time to onset of symptom relief of 1.28 hours versus placebo, and reported that secondary endpoints were also met. The company has stated that it expects to seek global regulatory approvals in the first half of 2026.

In March 2025, Pharvaris presented longer-term clinical data for deucrictibant at the AAAAI-WAO Joint Congress, referencing results across Phase II prophylaxis and on-demand studies and highlighting ongoing Phase III programs. In April 2025, the company said the European Commission granted orphan designation for deucrictibant for HAE.

Pharvaris has also expanded clinical development into related indications. In Q3 2025 reporting, the company referenced initiation of a pivotal Phase III study in acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). The same update reported cash and cash equivalents of €329 million as of September 30, 2025, and said runway extended into the first half of 2027 following a public offering that generated approximately $201 million in proceeds.